Differential diagnosis for abdominal pain should enclose the rare occurrence of venous thromboembolism
Introduction
Inflammatory bowel diseases (IBDs) are considered as favouring conditions for venous thromboembolism (VTE) (Danese et al., 2005 , Kappleman et al., 2011 , Grainge et al., 2010 , Guglielmi et al., 2005 , and Miehsler et al., 2004 . This extraintestinal manifestation is an important cause of mortality in patients with IBD (Quera et al., 2004 , Twing et al., 2005 , and Hatoum et al., 2005 . This rare condition, at least in noncirrhotic patients, infrequently involves uncommon sites as the splenic-mesentericportal vein system and may be associated with severe morbidity and mortality (Guglielmi et al., 2005) . This case report points out the rare occurrence of splenicmesenteric-portal vein system thrombosis as the first acute manifestation of ulcerative colitis in a young adult patient.
Several points define the peculiarity of the here described case: (i) the first onset sign of an ulcerative colitis by a rare occurrence, life-threatening thrombotic event in a very unusual site such as the portal-mesenteric vascular district indeed represents a challenge; (ii) the importance of an accurate multidisciplinary approach for a prompt, correct diagnosis may greatly influence the positive outcome of the disease; and (iii) the therapeutic choice and the effectiveness of an adequate duration of the anticoagulant therapy may significantly influence the disease prognosis. Given the scarce data available from the medical literature, the description of such an uncommon case with a favourable outcome may be of help in adding some knowledge for the clinical approach.
Case Report
A 32-year-old man was first referred to the emergency department (ED) of a suburban hospital because of severe, acute, and abdominal meso and epigastric pain. No signs of acute abdomen syndrome were reported, and the blood white cell count, serum amylase, and lipase levels as well as kidney and liver function markers were normal. Intravenous ketoprofen was administered with benefit, and the patient was dismissed from the hospital with the recommendation of undergoing an abdomen ultrasonography shortly.
On the subsequent day, still persisting the abdominal pain, the patient turned up to the ED of the University Hospital of Verona, where he promptly underwent an abdomen ultrasonography revealing a thrombotic portal vein obstruction.
An abdomen CT scan with contrast showed marked portal vein dilatation (3.5 cm) with characteristics of an aneurysmal-like enlargement at the site of the splenicportal vein confluence, which appeared wholly occupied by thrombotic material (Figure 1 ). A thrombus of 3 cm diameter extended also to the mesenteric vein. A moderate splenomegaly was documented while pancreas and liver parenchyma appeared normal with no evidence of intraand/or extrahepatic biliary ducts dilatation. The patient was then admitted to our internal medicine department (IMD).The patient reported no significant family or personal history of venous thromboembolism (VTE). He was a smoker, but there were no other clear risk factors for VTE. Nevertheless, the patient reported that, due to persistent constipation and occasional hematochezia in the two months prior to admission, he had undergone a proctosigmoidoscopy with diagnosis of an "aspecific proctitis." At physical examination, the epigastric and mesogastric regions were mildly painful. Peristaltic movements were normally at auscultation with negative Blumberg and Murphy signs. Cardiopulmonary examination was unremarkable. The weight was normal and the patient was afebrile. Laboratory tests (Table 1) 27 pg) associated with hyposideremia (54 μg/dl) and normal ferritinemia (205 ng/mL). White blood cells and platelets count, inflammatory markers, electrolytes, creatinine, activated partial thromboplastin time, international normalized ratio, total and direct bilirubin, total proteins concentration, albumin, and alkaline phosphatase were normal. The neoplastic markers were also negative. Homocysteine was slightly increased (16.5 µmol/L) in association with low folatemia (6,8 nmol/L) but normal vitamin B12 plasma concentrations (503 pmol/L). Lupus anticoagulant, antiphospholipid and anticardiolipin antibodies, coagulation protein C and S, antithrombin III, activated protein C resistance, factor V Leiden, and prothrombin 20210G>A mutations were negative; the patient was heterozygous for the MTHFR677C>T polymorphism. Thus, the portomesenteric thrombosis could be attributed to a complication of inflammatory bowel disease (IBD). Therefore, oral mesalazine (1600 mg three times a day) associated with rectaladministered mesalazine (2000 mg twice daily) and folic acid was commenced.
At discharge, the patient was asymptomatic and clinically stable while continuing the IBD therapy associated with warfarin. The patient was subsequently followed up in the outpatient clinic.
Forty-five days after discharge, the patient underwent contrast-enhanced magnetic resonance that showed resolution of the portomesenteric thrombosis, while the aneurysmal dilatation at the splenic-portal confluence was still detectable. About a year after the diagnosis, an abdominal ultrasonography confirmed a splenic-portal vein axis free from thrombotic material and the colonoscopy documented a quiescent state of IBD so that oral anticoagulant therapy could be discontinued.
Discussion
VTE infrequently involves uncommon sites as the splenic-mesenteric-portal vein system. Early diagnosis is often difficult because VTE can develop in asymptomatic patients (Maconi et al., 2012) , and the most recurrent symptom, that is, moderate-tosevere abdominal pain in the upper quadrants, is largely aspecific, as it occurred to our patient.
In the present case, the abdominal pain was likely due to VTE and not to IBD considering that the white blood cell count and the inflammatory markers were within the normal values and that other signs or symptoms as rectal bleeding or diarrhea were absent. This infrequent condition of a VTE in such site may be associated with severe morbidity and mortality (Hatoum et al., 2005 , Martinelli et al., 2008 , but the recent literature shows conflicting data (Maconi et al., 2012) .
The peculiarity of the present case refers to the onset of an ulcerative colitis at inactive stage by a rare occurrence, life-threatening thrombotic event in a very unusual site such as the portal-mesenteric vascular district that indeed represents a clinical challenge. Furthermore, the appropriate treatment and the duration of anticoagulant therapy are not consistently reported in the literature, so far, and the description of the effectiveness of the therapeutic approach in specific cases, At the first access to the ED, the patient was probably not adequately treated considering that the abdominal pain was acute and severe, and in such event, instrumental investigations (e.g., plain abdominal X-ray or ultrasonography) should have been performed as soon as possible. Moreover, in the differential diagnostic approach of epi-mesogastric pain in which the suspicion of peptic disease had to be considered, the administration of ketoprofen was to be avoided.
Imaging techniques (Doppler ultrasonography, CT-scan, and MRI) greatly contribute to early diagnosis (Hatoum et al., 2005 , Martinelli et al., 2008 . Reports on possible association with thrombophilic abnormalities are scarce (Martinelli et al., 2008) . In addition to classical primary or acquired thrombophilic conditions including the JAK-2 V617F mutation, liver cirrhosis, surgical injury to the portal venous system, gastrointestinal cancer, and IBD are listed among favouring conditions for the occurrence of splanchnic vein thrombosis (Martinelli et al., 2008) . IBD is a condition associated with a potential hypercoagulability state and with an incidence of thromboembolic events higher than in the general population (Kappleman et al., 2011 , Grainge et al., 2010 , and Miehsler et al., 2004 . The relationship between inflammatory bowel disease and platelet functions is well known, and the platelet aggregation response could be increased even in inactive phase patients (Andoh et al., 2006) .
Regarding IBD, Talbot et al. (1986) observed that VTE occurred in 1.3% of the patients during an 11-year follow-up study (Talbot et al., 1986) . Mesenteric and portal vein thromboses were mainly postsurgery complications, while 77% of peripheral venous thrombosis occurred spontaneously (Talbot et al., 1986) . In most cases (73%), the disease was in active phase as demonstrated by the finding of increased inflammatory markers (Talbot et al., 1986) . On the other hand, it has been observed that mesenteric thrombosis may develop even during clinical remission with a mean time of 24.6±13.5 years since IBD diagnosis (Quera et al., 2004 , Jackson et al., 2011 . A laboratory marker with sufficient predictability to identify patients at particular risk of VTE has not been identified, thus far (Quera et al., 2004) . Mortality among patients with portalmesenteric vein thrombosis is rather high, ranging from 25% to 50% (Guglielmi et al., 2005 , Talbot et al., 1986 (Amitrano et al., 2007) .
The issue of an appropriate anticoagulant therapy use in splanchnic vein thrombosis is even more complex than for other rare venous thrombosis for several reasons. Portal vein thrombosis often leads to severe sequelae such as portal hypertension, which in turn increases the risk of bleeding because of both esophageal varices and hypersplenism-related thrombocytopenia (Martinelli et al., 2008) . Indeed, the decision on the duration of oral anticoagulation should be individually tailored (Kappleman et al., 2011 , Twing et al., 2005 according to the risk/benefit ratio due to presence or absence of major risk factors for bleeding or recurrent thrombosis (De Stefano et al., 2010) . bleeding risk is low or absent, anticoagulant therapy should be continued until vessel recanalization is documented. In the presence of esophageal varices, an endoscopic bending and medical therapy with beta-blockers is suggested, while in the presence of thrombocytopenia, oral anticoagulation is to be avoided if platelet count is below 50,000/mmc (Martinelli et al., 2008) .
Considering the prolonged remission of IBD, as it refers to the here described case, oral anticoagulation was discontinued when portal-mesenteric vein axis was completely recanalized.
At five-year followup, the patient is asymptomatic, with a regular bowel function, in remission phase of ulcerative colitis disease. Abdominal ultrasonography shows no evidence of thrombi in the portal and mesenteric venous axis.
